Blindness News and Research RSS Feed - Blindness News and Research

Treating prediabetes patients could help prevent severe complications associated with diabetes

Treating prediabetes patients could help prevent severe complications associated with diabetes

Doctors at three leading research institutions and the American Diabetes Association report that treating patients with prediabetes as if they had diabetes could help prevent or delay the most severe complications associated with this chronic disease, which affects about thirty million people in the United States. [More]
Researchers reveal why RB1 gene mutations primarily cause retinoblastomas in children

Researchers reveal why RB1 gene mutations primarily cause retinoblastomas in children

Retinoblastoma is a childhood retinal tumor usually affecting children one to two years of age. Although rare, it is the most common malignant tumor of the eye in children. [More]
Celgene Global Health, DNDi expand partnership to identify new drug candidates for NTDs

Celgene Global Health, DNDi expand partnership to identify new drug candidates for NTDs

Celgene Global Health, a division of Celgene Corporation, and the Drugs for Neglected Diseases initiative strengthen their collaboration with a four-year Research Collaboration Agreement to identify and optimize new drug candidates for the treatment of neglected tropical diseases (NTDs). [More]
Dynamical glucometry may uncover new ways of understanding diabetes

Dynamical glucometry may uncover new ways of understanding diabetes

For millions of people in the United States living with Type 1 or Type 2 diabetes, measuring the daily rise and fall of blood glucose (sugar) is a way of life. [More]
Diabetes rates among U.S. adults stabilizing

Diabetes rates among U.S. adults stabilizing

Following a doubling of the incidence and prevalence of diabetes in the U.S. from 1990-2008, new data suggest a plateauing of the rate between 2008 and 2012 for adults, however the incidence continued to increase in Hispanic and non-Hispanic black adults, according to a study in the September 24 issue of JAMA. [More]
EYLEA Injection gets approval in Japan for treatment of myopic CNV

EYLEA Injection gets approval in Japan for treatment of myopic CNV

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare for EYLEA (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV). [More]
Research roundup: Home health nurses' workloads; readmissions at the VA; SHOP choices

Research roundup: Home health nurses' workloads; readmissions at the VA; SHOP choices

In anticipation of next year's premium announcements and given some information already made public, concerns have surfaced about the potential for double-digit percent increases in nongroup and small-group health insurance premiums. This analysis shows that, although average annual increases in small-group premiums over the past 13 years averaged roughly 5.5 percent, double-digit average premium increases are common for states and large metropolitan areas. [More]
UVA Center for Telehealth receives 2014 Governor's Technology Award

UVA Center for Telehealth receives 2014 Governor's Technology Award

The University of Virginia Center for Telehealth received a 2014 Governor's Technology Award for making it easier to access high-quality care and health education for patients across Virginia. [More]
FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted EYLEA (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). [More]
Cochrane Review rejects safety concerns regarding cheap alternative drug for treating eye disease

Cochrane Review rejects safety concerns regarding cheap alternative drug for treating eye disease

Health policies which favour using ranibizumab for treating eye disease in older people over safety concerns for a cheaper alternative should take account of a new Cochrane Review published today. [More]
New research shows statins could reduce common diabetes complications

New research shows statins could reduce common diabetes complications

The development of common diabetes complications that can lead to blindness and amputations could be reduced by taking statins, indicates new research published in The Lancet Diabetes & Endocrinology. [More]
Professor receives award for development of anti-angiogenic therapy for retinal disease

Professor receives award for development of anti-angiogenic therapy for retinal disease

Napoleone Ferrara, MD, distinguished professor of pathology and distinguished adjunct professor of ophthalmology at the University of California, San Diego School of Medicine and senior deputy director for basic sciences at UC San Diego Moores Cancer Center, was named today as one of seven recipients of the Ant-nio Champalimaud Vision Award in Lisbon, Portugal. [More]
BioLight Life Sciences declares first sale of IOPtiMate system in Hong Kong

BioLight Life Sciences declares first sale of IOPtiMate system in Hong Kong

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announces the first sale of an IOPtiMateā„¢ system in Hong Kong. [More]
Scientists identify how molecular motor essential for human development works

Scientists identify how molecular motor essential for human development works

Another mystery of the human body has been solved by scientists who have identified how a molecular motor essential for human development works. [More]
Transparency Life receives SBIR program grant to fund Phase 2a proof-of-concept study for MS

Transparency Life receives SBIR program grant to fund Phase 2a proof-of-concept study for MS

Transparency Life Sciences, LLC (TLS), the world's first clinical-stage drug development company based on open innovation, today announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive therapy for multiple sclerosis (MS). [More]
Using molecular imaging probes diabetic retinopathy can be detected at molecular level

Using molecular imaging probes diabetic retinopathy can be detected at molecular level

A new study published in the September issue of The FASEB Journal, identifies a novel strategy to diagnose the leading cause of blindness in adults, diabetic retinopathy, before irreversible structural damage has occurred. [More]
ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

Antisense Therapeutics Limited is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly. [More]
Tiny eye implant enables patients to battle glaucoma

Tiny eye implant enables patients to battle glaucoma

For the 2.2 million Americans battling glaucoma, the main course of action for staving off blindness involves weekly visits to eye specialists who monitor - and control - increasing pressure within the eye. [More]
Penn Medicine launches CAROT to build novel therapies for retinal and ocular disorders

Penn Medicine launches CAROT to build novel therapies for retinal and ocular disorders

The Perelman School of Medicine at the University of Pennsylvania has launched the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to build on its previous success developing novel therapies for the personalized diagnosis and treatment of retinal and ocular disorders. [More]
DNA testing for congenital cataracts can accurately diagnose diseases linked to childhood blindness

DNA testing for congenital cataracts can accurately diagnose diseases linked to childhood blindness

Researchers in the United Kingdom have demonstrated that advanced DNA testing for congenital cataracts can quickly and accurately diagnose a number of rare diseases marked by childhood blindness, according to a study published online today in Ophthalmology, the journal of the American Academy of Ophthalmology. [More]